177 related articles for article (PubMed ID: 20082362)
1. Model-based approaches for time-dependent dose finding with repeated binary data.
Benda N
Stat Med; 2010 May; 29(10):1096-106. PubMed ID: 20082362
[TBL] [Abstract][Full Text] [Related]
2. Combining multiple comparisons and modeling techniques in dose-response studies.
Bretz F; Pinheiro JC; Branson M
Biometrics; 2005 Sep; 61(3):738-48. PubMed ID: 16135025
[TBL] [Abstract][Full Text] [Related]
3. Estimating treatment efficacy over time: a logistic regression model for binary longitudinal outcomes.
Choi L; Dominici F; Zeger SL; Ouyang P
Stat Med; 2005 Sep; 24(18):2789-805. PubMed ID: 16134133
[TBL] [Abstract][Full Text] [Related]
4. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.
Bekele BN; Shen Y
Biometrics; 2005 Jun; 61(2):343-54. PubMed ID: 16011680
[TBL] [Abstract][Full Text] [Related]
5. Hypothesis testing and Bayesian estimation using a sigmoid Emax model applied to sparse dose-response designs.
Thomas N
J Biopharm Stat; 2006; 16(5):657-77. PubMed ID: 17037264
[TBL] [Abstract][Full Text] [Related]
6. Proof of concept and dose estimation with binary responses under model uncertainty.
Klingenberg B
Stat Med; 2009 Jan; 28(2):274-92. PubMed ID: 19012269
[TBL] [Abstract][Full Text] [Related]
7. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
8. A method for therapeutic dose selection in a phase II clinical trial using contrast statistics.
Wakana A; Yoshimura I; Hamada C
Stat Med; 2007 Feb; 26(3):498-511. PubMed ID: 16596575
[TBL] [Abstract][Full Text] [Related]
9. Model-based dose finding under model uncertainty using general parametric models.
Pinheiro J; Bornkamp B; Glimm E; Bretz F
Stat Med; 2014 May; 33(10):1646-61. PubMed ID: 24302486
[TBL] [Abstract][Full Text] [Related]
10. An adaptive dose-finding design incorporating both toxicity and efficacy.
Zhang W; Sargent DJ; Mandrekar S
Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478
[TBL] [Abstract][Full Text] [Related]
11. Design and analysis of dose-finding studies combining multiple comparisons and modeling procedures.
Pinheiro J; Bornkamp B; Bretz F
J Biopharm Stat; 2006; 16(5):639-56. PubMed ID: 17037263
[TBL] [Abstract][Full Text] [Related]
12. The analysis of longitudinal polytomous data: generalized estimating equations and connections with weighted least squares.
Miller ME; Davis CS; Landis JR
Biometrics; 1993 Dec; 49(4):1033-44. PubMed ID: 8117899
[TBL] [Abstract][Full Text] [Related]
13. Marginal modeling of binary cross-over data.
Becker MP; Balagtas CC
Biometrics; 1993 Dec; 49(4):997-1009. PubMed ID: 8117910
[TBL] [Abstract][Full Text] [Related]
14. Improving the estimation of change from baseline in a continuous outcome measure in the clinical trial setting.
Mayer-Hamblett N; Kronmal RA
Contemp Clin Trials; 2005 Feb; 26(1):2-16. PubMed ID: 15837448
[TBL] [Abstract][Full Text] [Related]
15. Bayesian optimal designs for a quantal dose-response study with potentially missing observations.
Baek I; Zhu W; Wu X; Wong WK
J Biopharm Stat; 2006; 16(5):679-93. PubMed ID: 17037265
[TBL] [Abstract][Full Text] [Related]
16. Using the partitioning principle to adaptively design dose-response studies.
Ling X; Hsu J
J Biopharm Stat; 2006; 16(5):733-43. PubMed ID: 17037268
[TBL] [Abstract][Full Text] [Related]
17. An improved method of evaluating drug effect in a multiple dose clinical trial.
Shen L
Stat Med; 2001 Jul; 20(13):1913-29. PubMed ID: 11427949
[TBL] [Abstract][Full Text] [Related]
18. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
Kimani PK; Stallard N; Hutton JL
Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
[TBL] [Abstract][Full Text] [Related]
19. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
Yin G; Li Y; Ji Y
Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
[TBL] [Abstract][Full Text] [Related]
20. Optimal adaptive design in clinical drug development: a simulation example.
Maloney A; Karlsson MO; Simonsson US
J Clin Pharmacol; 2007 Oct; 47(10):1231-43. PubMed ID: 17906158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
